New experimental breast cancer therapies directed against novel targets are currently in clinical These experimental agents are likely to be effective for a niche of breast cancers with specific “driver mutations”. The ability to perform comprehensive molecular profiling of individual tumors has rapidly expanded over the last few years, and new DNA sequencing technologies require relatively limited quantities of fresh or archived paraffin-embedded or snap-frozen tumor tissue and provide rapid turnaround of sequencing results within a few weeks or less. All these technologies provide an unprecedented opportunity to identify patients with rare “driver” molecular alternations that are candidates for proof-of-concept clinical trials with matched targeted therapy, in the context of basket trials. The aim of this chapter on molecular profiling is to summarize the known recurrent molecular alterations in breast cancer that are potentially amenable to investigational targeted therapy, to provide an overview of the existing technological platforms for molecular profiling and ongoing or planned institutional/national screening initiatives and to outline a vision for molecular screening that may be integrated into the future activities of breast cancer research.

Cancer evolution as the new frontier of precision medicine / G. Curigliano (HANDBOOK OF EXPERIMENTAL PHARMACOLOGY). - In: Mechanisms of Drug Resistance in Cancer Therapy / [a cura di] M. Mandalà, E. Romano. - [s.l] : Springer, 2018. - ISBN 9783030105068. - pp. 289-297

Cancer evolution as the new frontier of precision medicine

G. Curigliano
Writing – Review & Editing
2018

Abstract

New experimental breast cancer therapies directed against novel targets are currently in clinical These experimental agents are likely to be effective for a niche of breast cancers with specific “driver mutations”. The ability to perform comprehensive molecular profiling of individual tumors has rapidly expanded over the last few years, and new DNA sequencing technologies require relatively limited quantities of fresh or archived paraffin-embedded or snap-frozen tumor tissue and provide rapid turnaround of sequencing results within a few weeks or less. All these technologies provide an unprecedented opportunity to identify patients with rare “driver” molecular alternations that are candidates for proof-of-concept clinical trials with matched targeted therapy, in the context of basket trials. The aim of this chapter on molecular profiling is to summarize the known recurrent molecular alterations in breast cancer that are potentially amenable to investigational targeted therapy, to provide an overview of the existing technological platforms for molecular profiling and ongoing or planned institutional/national screening initiatives and to outline a vision for molecular screening that may be integrated into the future activities of breast cancer research.
Breast cancer; Driver mutations; Personalized medicine; Biochemistry; Pharmacology, Toxicology and Pharmaceutics (all)
Settore MED/06 - Oncologia Medica
Book Part (author)
File in questo prodotto:
File Dimensione Formato  
Curigliano_CancerEvolutionNewFrontier_inDNA_Repair.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 142.74 kB
Formato Adobe PDF
142.74 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/623269
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact